Literature DB >> 6849861

Slow-release artificial tear inserts in the treatment of dry eyes resulting from the oculomucocutaneous syndrome.

P Wright, R Vogel.   

Abstract

Patients with dry eyes resulting from the practolol syndrome present a therapeutic challenge. Very frequent instillation of preservative-free drops are the only therapy in most cases. Using an entirely new agent--a hydrophilic polymer in insert form--we have provided in this open study an alternative therapy which shows some subjective and objective advantages. Few patients experienced problems, and none left the study because of failure of retention of the insert. Some patients preferred the cooling, soothing effects of frequent drops. The problems in mounting a clinical trial of this sort are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849861      PMCID: PMC1040072          DOI: 10.1136/bjo.67.6.393

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Untoward effects associated with practolol administration: oculomucocutaneous syndrome.

Authors:  P Wright
Journal:  Br Med J       Date:  1975-03-15

2.  A soluble sustained-release ophthalmic delivery unit.

Authors:  I M Katz; W M Blackman
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

3.  Tear substitutes in the treatment of dry eyes.

Authors:  M A Lemp
Journal:  Int Ophthalmol Clin       Date:  1973

4.  A clinical study of slow-releasing artificial tears.

Authors:  D W Lamberts; D P Langston; W Chu
Journal:  Ophthalmology       Date:  1978-08       Impact factor: 12.079

5.  Slow-release artificial tears and the treatment of keratitis sicca.

Authors:  J I Katz; H E Kaufman; C Breslin; I M Katz
Journal:  Ophthalmology       Date:  1978-08       Impact factor: 12.079

  5 in total
  1 in total

1.  Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis.

Authors:  J C Hill
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.